| HOME >> BIOLOGY >> TECHNOLOGY |
n. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.
Forward-looking statements
This press release contains forward-looking statements, including
statements regarding future results, performance or achievements. These
statements involve known and unknown risks, uncertainties and other factors
which may cause our actual results, performance or achievements to be
materially different from any future results, performances or achievements
expressed or implied by the forward-looking statements. These statements
reflect our current views with respect to future events and are based on
assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these forward-looking
statements. Some of the factors that could affect the forward-looking
statements contained herein include that the Phase II clinical trials of
peramivir may not be successful, that the Phase II trial of BCX-4208 for
psoriasis may not be successfully completed, that development and
commercialization of Fodosine(TM) in both T-ALL and CTCL may not be
successful, that we may not resolve satisfactorily the particulate matter
issue with the intravenous formulation of Fodosine(TM), that DHHS could
reduce or eliminate funding for peramivir, that we or our licensees may not
be able to enroll the required number of subjects in planned clinical
trials of our product candidates and that such clinical trials may not be
successfully completed, that BioCryst or its licensees may not commence as
expected additional human clinical trials with our product candidates, that
our product candidates may not receive required regulatory clearances from
the FDA, that ongoing and future clinical trials may not have positive
results, that we may not be able to complete successfully the Phase IIb
trials for Fodosine(TM) that are currently planned to be pivotal, that we
m
'/>"/>
| SOURCE BioCryst Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |